CA2205442C - Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures - Google Patents

Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures Download PDF

Info

Publication number
CA2205442C
CA2205442C CA002205442A CA2205442A CA2205442C CA 2205442 C CA2205442 C CA 2205442C CA 002205442 A CA002205442 A CA 002205442A CA 2205442 A CA2205442 A CA 2205442A CA 2205442 C CA2205442 C CA 2205442C
Authority
CA
Canada
Prior art keywords
nsaid
gum
composition
weight
aspirin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002205442A
Other languages
English (en)
Other versions
CA2205442A1 (fr
Inventor
David R. Friend
Karen Yu
Jagdish Parasrampuria
Eric H. Kuhrts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Development AB
Original Assignee
Amarin Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Development AB filed Critical Amarin Development AB
Publication of CA2205442A1 publication Critical patent/CA2205442A1/fr
Application granted granted Critical
Publication of CA2205442C publication Critical patent/CA2205442C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composition pharmaceutique à administration par voie orale, destinée à réduire l'irritation gastrique due à un anti-inflammatoire non stéroïdien dans la partie supérieure du tube digestif d'un mammifère. La composition comprend (a) une gomme hydrocolloïdale acceptable sur le plan pharmaceutique pouvant être obtenue à partir des plantes supérieures, en quantité suffisante pour protéger les muqueuses, (b) un autre excipient en quantité suffisante pour favoriser la dispersion, et (c) un anti-inflammatoire non stéroïdien en quantité suffisante pour posséder une action thérapeutique. Sont aussi présentés une technique de préparation de la composition et un procédé visant à réduire, par administration de la composition, l'irritation gastrique due à un anti-inflammatoire non stéroïdien. Est également présentée une composition particulièrement utile pour la préparation d'une suspension aqueuse.
CA002205442A 1994-12-01 1995-11-30 Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures Expired - Fee Related CA2205442C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34760194A 1994-12-01 1994-12-01
US08/347,601 1994-12-01
PCT/US1995/015599 WO1996016639A1 (fr) 1994-12-01 1995-11-30 Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures

Publications (2)

Publication Number Publication Date
CA2205442A1 CA2205442A1 (fr) 1996-06-06
CA2205442C true CA2205442C (fr) 2003-01-21

Family

ID=23364417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205442A Expired - Fee Related CA2205442C (fr) 1994-12-01 1995-11-30 Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures

Country Status (8)

Country Link
EP (1) EP0804169A4 (fr)
JP (1) JPH10509982A (fr)
AU (1) AU690417B2 (fr)
CA (1) CA2205442C (fr)
FI (1) FI972305A0 (fr)
MX (1) MX9704079A (fr)
NO (1) NO972485L (fr)
WO (1) WO1996016639A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
AU695734B2 (en) * 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
IL141236A0 (en) * 1998-08-21 2002-03-10 Novartis Ag New oral formulations for 5-ht4 agonists or antagonists
SE0003125D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1327938A (en) * 1969-12-17 1973-08-22 Sucrest Corp Composition for use in forming tablets
DE2130545A1 (de) * 1971-06-19 1972-12-21 Merck Patent Gmbh Pharmazeutischer Formkoerper
WO1986006627A1 (fr) * 1985-05-15 1986-11-20 Riker Laboratories, Inc. Procedes et compositons de theophylline a liberation entretenue
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
JP2628231B2 (ja) * 1992-12-30 1997-07-09 エフ エム シー コーポレーション 放出調整賦形剤として容易に入手できるコンニャクグルコマンナン

Also Published As

Publication number Publication date
NO972485L (no) 1997-07-31
MX9704079A (es) 1997-12-31
FI972305A (fi) 1997-05-30
EP0804169A4 (fr) 1998-08-19
AU690417B2 (en) 1998-04-23
FI972305A0 (fi) 1997-05-30
EP0804169A1 (fr) 1997-11-05
CA2205442A1 (fr) 1996-06-06
NO972485D0 (no) 1997-05-30
WO1996016639A1 (fr) 1996-06-06
JPH10509982A (ja) 1998-09-29
AU4595196A (en) 1996-06-19

Similar Documents

Publication Publication Date Title
EP0234670B1 (fr) Formulation pharmaceutique à libération retardée contenant de la gomme xanthane
US5023245A (en) Improved niacin formulation
US4983398A (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5096714A (en) Prolonged release drug tablet formulations
CA2301132C (fr) Comprimes de methylcellulose a desintegration rapide
US5445826A (en) Delivery system containing a gel-forming dietary fiber and a drug
CA2354057C (fr) Comprime a liberation prolongee contenant un hydrocolloide et un ether de cellulose
US7011848B1 (en) Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor
PL177315B1 (pl) Lek w postaci tabletek o przedłużonym uwalnianiu substancji czynnej
JPH05246861A (ja) ポリカルボフィルカルシウム含有製剤
CA2205442C (fr) Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures
US5993860A (en) NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
AU709413B2 (en) Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
MXPA97004043A (en) Assortment of pharmacy of sustained release using a rubber of hydrocoloid in powder obtained from top plants
CA2030448A1 (fr) Formulation pour melange de boisson a la niacine
AU744483B2 (en) Compressed compositions comprising clarified xanthan gum
AU2009200874A1 (en) Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
MXPA01006202A (es) Formulacion de liberacion controlada de sodio de divalproex
MXPA00001856A (en) Rapidly disintegrating methylcellulose tablets

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed